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‘Menopause is a cardiovascular 
risk factor for endothelial 
dysfunction … It also represents 
a unique opportunity to study 
the effect of endothelial 
dysfunction in healthy women 
and predicts the development of 
atherosclerosis and 
atherosclerosis-related disease.’
The endothelium is a major regulator of homeos-
tasis and exerts a number of vasoprotective effects,
such as vasodilation, inhibition of inflammatory
responses and suppression of smooth muscle cell
growth. Dysfunction of the endothelium thus
causes reduction or abolition of these vaso-
protective effects. Factors that lead to endothelial
dysfunction (ED) include a reduction in nitric
oxide (NO) production, increased oxidative stress
and a decrease in NO bioavailability, whereas
endothelium-derived contracting factors are
increased. This imbalance leads to an impairment
of endothelium-dependent vasodilation, which
represents the functional characteristic of ED.
Moreover, ED also comprises a specific state of
‘endothelial activation’, which is characterized by a
proinflammatory, proliferative and procoagulatory
milieu that favors all stages of atherogenesis [1,2].
Hence, ED it is considered a systemic disorder
and a key variable in the pathogenesis of athero-
sclerosis and its complications. Current evidence
suggests that endothelial status is not determined
solely by the individual risk-factor burden but,
rather, may be regarded as an integrated index of
all atherogenic and atheroprotective factors
present in an individual. ED reflects a vascular
phenotype prone to atherogenesis, and may
therefore serve as a marker of the inherent
atherosclerotic risk in an individual. In line with
this hypothesis, dysfunction of either the coro-
nary or peripheral vascular endothelium was
shown to constitute an independent predictor of
cardiovascular events, providing valuable prog-
nostic information additional to that derived
from conventional risk-factor assessment [3].
The healthy endothelium, in fact, not only medi-
ates endothelium-dependent vasodilation, but
also actively suppresses thrombosis, vascular
inflammation and hypertrophy. Nitric oxide is a
particularly important mediator of both
endothelium-dependent vasodilation and anti-
inflammatory and antithrombotic effects of the
endothelium, and endothelium-dependent vaso-
motion is therefore thought to represent a ‘read-
out’ of other important functions of
the endothelium.
It is now well recognized that high-resolution
ultrasound study of endothelium-dependent
brachial artery flow mediated dilation (FMD) is
a useful tool for assessing the change in vasomo-
tor response in relation to risk factors, aging and
drug therapy [4]. This noninvasive technique is
feasible and repeatable, and we have been per-
forming it for a long time in our Women’s
Clinic. This ‘imaging’ technique is based on the
fact that ED is not confined to the coronary
arteries but, rather, represents a systemic disorder
that also affects peripheral vascular beds, includ-
ing both conduit arteries and small-resistance
vessels in the extremities [5]. Several studies have
confirmed that FMD of the brachial artery is
impaired in patients with various atherosclerotic
risk factors, including advanced age, hyper-
lipidemia, hypertension, diabetes mellitus,
smoking and postmenopausal status [6–10]. Some
studies indicated that the risk of developing ED
increases with the number of risk factors present
in an individual. In addition, assuming that the
potential to alter endothelial function may vary
between different risk factors, it may be specu-
lated that certain clusters of risk factors, such as
those observed in patients with metabolic syn-
drome, may have a greater impact on endothelial
function than other risk-factor combinations.
Furthermore, given its pivotal role in the athero-
genic process, ED may be regarded as the ‘ulti-
mate risk of the risk factors’, indicating the
existence of a specific atherogenic vascular
milieu (Figure 1) [3].
Our specific interest has been the study of ED
in postmenopausal women. Menopause, in fact,
is a cardiovascular risk factor for ED, independ-
ent from the presence of other risk factors. It also
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Figure 1. Endothelial dysfunction as the ‘risk of the risk factors’.
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Endothelial dysfunction: ‘the risk of the risk factors’
Traditional risk factors
represents a unique opportunity to study the
effect of ED in healthy women and predicts the
development of atherosclerosis and athero-
sclerosis-related disease. For all these reasons it
may be ‘common’ in postmenopausal women. 
The evaluation of ED in postmenopausal
women started in 1996 when the Women’s
Clinic was set up at our Institute. This is a clinic
dedicated to the study, prevention and treatment
of menopause-related disease.
The ‘core’ of our clinical research in the last
10 years has been to speculate on the fact that
ED is common in postmenopausal, healthy
women, but only in some women may predict
the development of hypertension and/or diabe-
tes and, finally, of atherosclerosis. Therefore it
is not clear whether ED is actually a conse-
quence or, rather, the cause of hypertension
and/or diabetes.
Therefore our clinical research provided the
first opportunity to assess relationship between
endothelial vasomotor function and incidence
of hypertension in a cohort of healthy post-
menopausal women [11]. In this case, we con-
ducted a prospective cohort study on 952
apparently healthy postmenopausal women
with initially normal levels of blood pressure
and no history of hypertension. All participants
were followed up for a mean period of 3.6 ± 0.7
years. Endothelial function was measured as
FMD of the brachial artery using high-resolution
ultrasound. During follow-up, 112 women
developed hypertension. The adjusted relative
risk for women with FMD of 3.5 or less (lowest
quartile) was 5.77 (95% confidence interval
[CI]: 4.34–8.10) versus women with FMD of
5.5 or greater (highest quartile, referent). Each
one-unit decrease of FMD was associated with
a significant 16% (95% CI: 12–33%) increase
in the multiple-adjusted relative risk of incident
hypertension (Figure 2). Our study demonstrates
that, in healthy, normotensive postmenopausal
women, endothelial-dependent vasodilation is a
parameter able to significantly predict the
future development of hypertension, independ-
ently of numerous well-known risk factors and
with a high correlation with the degree of
impaired ED. The role of severely impaired
endothelial function in predicting ED-related
diseases was reconfirmed in a cohort of healthy,
nonobese normoglycemic postmenopausal
women of our Women’s Clinic, followed-up for
approximately 5 years [12]. In this population,
each one-unit decrease in %FMD was associated
with a significant 32% (95% CI: 22–48) increase
in the multiple-adjusted relative risk of incident
diabetes. This could suggest that an impaired
endothelial function may also play a fundamental
role in diabetogenesis in postmenopausal
women. The fact that hypertension may predict
the development of diabetes is well known,
behaving to the subset of insulin-resistance,
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which is particularly relevant in post-
menopausal women, who are, therefore, also at
high risk of developing metabolic syndrome.
No prospective data exist regarding the inci-
dence rate of hypertension in postmenopausal
women with Type 2 diabetes mellitus. In a
recent study, we assessed the risk of developing
hypertension in 102 diabetic (Type 2 diabetes
mellitus) postmenopausal women, compared
with 538 nondiabetic women. Compared with
the nondiabetic group, women with Type 2
diabetes mellitus had a statistically significant
higher risk of developing hypertension; in our
prospective study on the incidence of hyper-
tension, therefore the presence of Type 2 diabe-
tes was found to be a potent independent risk
determinant [13].
Therefore, hypertension, diabetes and athero-
sclerosis share common pathophysiology and eti-
opathogenesis suggesting that they spring from a
common soil, which is represented by ED.
For this reason, we believe ED plays a pivotal
role in postmenopause, either for risk factors
and/or specific disease, or for prognosis. In fact
we demonstrated its prognostic role in hyperten-
sion in a study where we assessed whether antihy-
pertensive treatment was effective in modifying
ED in postmenopausal women and whether an
improvement of FMD in response to treatment,
as an expression of a reversible ED, could pro-
vide a more favorable prognosis in the studied
population [14]. A total of 400 consecutive post-
menopausal women with mild-to-moderate
hypertension and impaired FMD underwent
ultrasonography of the brachial artery at base-
line, and after 6 months, while optimal control
of blood pressure was achieved using anti-
hypertensive therapy. They were then followed
up for a mean period of 67 months. After
6 months of treatment, FMD had not changed in
150 (37.5%) of 400 women (group 1), whereas it
had significantly improved in the remaining
250 women (62.5%) (group 2). During follow-
up, we noticed 32 events (3.50/100 person-years)
in group 1 and 15 events (0.51/100 person-years)
in group 2 (p < 0.0001). Moreover, 32 (21.3%)
of 150 women experienced a nonfatal cardiovas-
cular event in group 1 (persistent impaired
FMD) (3.50 events/100 patient years) versus 15
(6.0%) of 250 women in group 2 (improved
FMD) (0.51 events/100 patient-years)
(p < 0.0001) (Figure 3). Our study demonstrated
that in most hypertensive postmenopausal
women, a significant improvement in FMD may
be obtained after 6 months of optimized therapy
in most, and it also clearly identifies patients
with a more favorable prognosis. Conversely, a
higher risk of nonfatal cardiovascular events can
be predicted by a noninvasive variable: a lack of
change in FMD. 
‘…Hypertension, diabetes and 
atherosclerosis share common 
pathophysiology and etiopathogenesis, 
suggesting that they spring from a 
common soil, which is represented 
by endothelial dysfunction’.
This study has been included in two different
meta-analyses both describing the strong associ-
ation between coronary or peripheral ED and
cardiovascular events [15,16], using different tech-
niques (either invasive and noninvasive) in dif-
ferent populations, our study being the only one
related to postmenopausal women. Finally, after
the evidence showing that ED has a pivotal role
in postmenopausal women, for both ethiopatho-
genesis and prognosis, we have demonstrated the
importance of using endothelial active-drugs to
treat ED-related disease, such as hypertension.
In four groups of hypertensive postmenopausal
women, we demonstrated that blood pressure
could be reduced in monotherapy with four
Figure 2. Relative risk of developing hypertension in relation 
to the percentage of flow-mediated dilation quartiles.
 
Adapted from [11].
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different classes of drug, but only with
angiotensin-converting enzyme-(ACE) inhibitors
was it possible to not only reduce blood pressure,
but also improve endothelial function.
 ‘…the most promising therapeutic 
objective in order to reduce the global 
cardiovascular risk in this specific 
population is to treat endothelial 
dysfunction.’
In conclusion, ED is common in post-
menopausal women, but it may predict cardio-
vascular disease in only some of them and when
particularly impaired. The strongest association
is among ED, diabetes, hypertension and athero-
sclerosis. Currently, the most promising thera-
peutic objective in order to reduce the global
cardiovascular risk in this specific population is
to treat ED.
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Figure 3. Cumulative survival rates, free of hospital admission, 
for cardiovascular events in two study groups.
 
Cumulative survival rates, free of hospital admission, for cardiovascular events 
according to persistent impaired (group 1 = dashed line) or improved (group 2 = 
dotted line) endothelium-derived FMD. 
FMD: Flow-mediated dilation.
Adapted from [14].
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